Related Experiment Video
Updated: Jun 12, 2025
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
Pluripotent stem cell-derived CTLs targeting FGFR3-TACC3 fusion gene in osteosarcoma
Haibo Zhan1, Jun Xiao1, Shoujie Shi1
1Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China; Artificial Joints Engineering and Technology Research Center of Jiangxi Province, No. 17, Yongwaizheng Street, Nanchang, Jiangxi Province 330006, China.
Abstract:
Osteosarcoma, a highly aggressive bone cancer, poses significant treatment challenges. This study investigates a novel approach utilizing induced pluripotent stem cells (iPSCs) engineered with the FGFR3-TACC3 fusion gene to generate cytotoxic T lymphocytes (CTLs) targeting osteosarcoma. The aim was to assess the efficacy of iPSC-derived CTLs in combating osteosarcoma progression. Abnormal expression of the FGFR3-TACC3 fusion gene was confirmed in osteosarcoma samples. iPSCs were successfully modified to express the fusion gene and were then differentiated into CTLs. In vitro experiments demonstrated that these modified CTLs effectively killed osteosarcoma cells, induced apoptosis, and inhibited migration and invasion. Findings were validated in in vivo experiments. This study suggests that iPSC-derived CTLs targeting FGFR3-TACC3 hold promise for personalized immunotherapy against osteosarcoma.
Insights
This study engineered stem cells to create immune cells targeting osteosarcoma by using the FGFR3-TACC3 gene. These engineered cells effectively fought osteosarcoma in lab and animal studies, showing promise for new cancer treatments.
Area of Science:
- Oncology
- Immunotherapy
- Stem Cell Biology
Background:
- Osteosarcoma is an aggressive bone cancer with limited treatment options.
- The FGFR3-TACC3 fusion gene is abnormally expressed in osteosarcoma.
- Targeting specific genetic mutations offers a potential avenue for novel cancer therapies.
Purpose of the Study:
- To investigate the efficacy of induced pluripotent stem cell (iPSC)-derived cytotoxic T lymphocytes (CTLs) engineered to target the FGFR3-TACC3 fusion gene in osteosarcoma.
- To assess the potential of this approach as a personalized immunotherapy.
Main Methods:
- Osteosarcoma samples were analyzed for FGFR3-TACC3 expression.
- iPSCs were genetically modified to express the FGFR3-TACC3 fusion gene.
- Modified iPSCs were differentiated into CTLs.
- In vitro and in vivo experiments were conducted to evaluate CTL efficacy.
Main Results:
- Abnormal FGFR3-TACC3 expression was confirmed in osteosarcoma.
- iPSC-derived CTLs targeting FGFR3-TACC3 were successfully generated.
- These modified CTLs demonstrated significant killing of osteosarcoma cells in vitro.
- CTLs inhibited osteosarcoma cell migration and invasion and induced apoptosis.
- In vivo studies validated the therapeutic potential.
Conclusions:
- iPSC-derived CTLs targeting FGFR3-TACC3 represent a promising strategy for osteosarcoma immunotherapy.
- This approach may offer a basis for personalized cancer treatment by targeting specific genetic alterations.
